Association between time in range, a novel measurement of glycemic control and islet secretory function in chinese patients with type 2 diabetes mellitus—An observational study

Time in range assessed by capillary blood glucose in relation to insulin sensitivity and β‐cell function in patients with type 2 diabetes mellitus: A cross‐sectional study in China

“…Furthermore, multinomial regression analysis revealed that 60 and 120 min insulin values, HOMA-b, and IAUC 0-120 /GAUC 0-120 were independent protective factors for the achievement of the target TIR (TIR > 70%), indicating that a relatively favorable islet reserve function is instrumental in controlling glucose fluctuations. Our results are consistent with those of two studies, which found that postprandial b-cell function affects glucose fluctuations estimated by CGM in individuals with type 2 diabetes mellitus 13,14 . The consistency in the results is possibly related to the similar clinical characteristics of the patients who participated in these studies.…”

“…Glycemic fluctuation has proven to be associated with impaired β‐cell function 13 . A recent study suggested that TIR calculated using CGM was associated with islet secretory function in patients with type 2 diabetes mellitus 14 . However, the association between insulin sensitivity and TIR in patients with type 2 diabetes mellitus remains unclear.…”

Association between residual islet beta‐cell function and achieving the target of time in range in inpatients with type 2 diabetes undergoing antidiabetic treatment: An observation study

“…In this study, we showed that beta-cell function (ISSI2) was positively associated with TIR, which was consistent with published studies. 5,7,17 Notably, we also found that lower ISSI2 was associated with a decreased number achieving TIR and TAR targets, indicating that preserving beta-cell function could be critical for controlling glycaemic level within a recommended range. Glucose-stimulated insulin secretion, especially early-phase insulin secretion, can lower postprandial glucose by stimulating glucose uptake in peripheral tissues and inhibiting glucagon-mediated endogenous glucose production.…”

“…Besides insulin, glucagon is another important hormone that regulates glucose homeostasis. Studies have proved that patients with aberrant glucagon secretion are more prone to have insulin‐induced hypoglycaemia and postprandial hyperglycaemia, leading to higher glycaemic fluctuations 7,27 . The functional integrity of glucagon secretion depends on the preserved regulation of insulin secretion, 28 while the decline of beta‐cell function might induce alpha cell dysfunction 29,30 .…”

“…Previous studies have shown that, both in insulin‐treated type 1 diabetes or oral hypoglycaemic agent (OHA)‐treated type 2 diabetes (T2D), a better residual islet beta‐cell function was associated with higher TIR and less glycaemic variability 5,6 . Another study also proved that TIR was positively associated with islet secretory function in patients with T2D 7 . However, it remains unclear whether the beta‐cell function of diabetes patients may influence achieving the target of TIR.…”